Candidate genes in gastric cancer identified by constructing a weighted gene co-expression network

被引:46
作者
Chen, Jian [1 ,2 ]
Wang, Xiuwen [1 ]
Hu, Bing [2 ]
He, Yifu [2 ]
Qian, Xiaojun [2 ]
Wang, Wei [2 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Shandong, Peoples R China
[2] Anhui Prov Hosp, Dept Chemotherapy, Hefei, Anhui, Peoples R China
基金
中国国家自然科学基金;
关键词
Gastric cancer; Weighted gene co-expression network analysis; Candidate gene; Histologic grade; Overall survival; Pathologic T stage; FOLLISTATIN-LIKE; 1; REGULATORY NETWORKS; MATRIX PROTEINS; EXPRESSION; DISEASES; OVARIAN; MARKER; GROWTH;
D O I
10.7717/peerj.4692
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background. Gastric cancer (GC) is one of the most common cancers with high mortality globally. However, the molecular mechanisms of GC are unclear, and the prognosis of GC is poor. Therefore, it is important to explore the underlying mechanisms and screen for novel prognostic markers and treatment targets. Methods. The genetic and clinical data of GC patients in The Cancer Genome Atlas (TCGA) was analyzed by weighted gene co-expression network analysis (WGCNA). Modules with clinical significance and preservation were distinguished, and gene ontology and pathway enrichment analysis were performed. Hub genes of these modules were validated in the TCGA dataset and another independent dataset from the Gene Expression Omnibus (GEO) database by t-test. Furthermore, the significance of these genes was confirmed via survival analysis. Results. We found a preserved module consisting of 506 genes was associated with clinical traits including pathologic T stage and histologic grade. PDGFRB, COL8A1, EFEMP2, FBN1, EMILIN1, FSTL1 and KIRREL were identified as candidate genes in the module. Their expression levels were correlated with pathologic T stage and histologic grade, also affected overall survival of GC patients. Conclusion. These candidate genes may be involved in proliferation and differentiation of GC cells. They may serve as novel prognostic markers and treatment targets. Moreover, most of them were first reported in GC and deserved further research.
引用
收藏
页数:19
相关论文
共 41 条
[1]   Comparing Statistical Methods for Constructing Large Scale Gene Networks [J].
Allen, Jeffrey D. ;
Xie, Yang ;
Chen, Min ;
Girard, Luc ;
Xiao, Guanghua .
PLOS ONE, 2012, 7 (01)
[2]   Role of platelet-derived growth factors in physiology and medicine [J].
Andrae, Johanna ;
Gallini, Radiosa ;
Betsholtz, Christer .
GENES & DEVELOPMENT, 2008, 22 (10) :1276-1312
[3]   Mitotic cell death caused by follistatin-like 1 inhibition is associated with up-regulated Bim by inactivated Erk1/2 in human lung cancer cells [J].
Bae, Kieun ;
Park, Kyoung Eun ;
Han, Jihye ;
Kim, Jongkwang ;
Kim, Kyungtae ;
Yoon, Kyong-Ah .
ONCOTARGET, 2016, 7 (14) :18076-18084
[4]  
Bang YJ, 2010, LANCET, V376, P1302
[5]   Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis-025EFa differential expression and functional analysis [J].
Chan, Queeny K. Y. ;
Ngan, Hextan Y. S. ;
Ip, Philip P. C. ;
Liu, Vincent W. S. ;
Xue, W. C. ;
Cheung, Annie N. Y. .
CARCINOGENESIS, 2009, 30 (01) :114-121
[6]   Fibrillin-1 (FBN-1) a new marker of germ cell neoplasia in situ [J].
Cierna, Z. ;
Mego, M. ;
Jurisica, I. ;
Machalekova, K. ;
Chovanec, M. ;
Miskovska, V. ;
Svetlovska, D. ;
Kalavska, K. ;
Rejlekova, K. ;
Kajo, K. ;
Mardiak, J. ;
Babal, P. .
BMC CANCER, 2016, 16
[7]   CD99 is a novel prognostic stromal marker in non-small cell lung cancer [J].
Edlund, Karolina ;
Lindskog, Cecilia ;
Saito, Akira ;
Berglund, Anders ;
Ponten, Fredrik ;
Goransson-Kultima, Hanna ;
Isaksson, Anders ;
Jirstrom, Karin ;
Planck, Maria ;
Johansson, Leif ;
Lambe, Mats ;
Holmberg, Lars ;
Nyberg, Fredrik ;
Ekman, Simon ;
Bergqvist, Michael ;
Landelius, Per ;
Lamberg, Kristina ;
Botling, Johan ;
Ostman, Arne ;
Micke, Patrick .
INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (10) :2264-2273
[8]  
Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]
[9]   Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].
Fuchs, Charles S. ;
Tomasek, Jiri ;
Yong, Cho Jae ;
Dumitru, Filip ;
Passalacqua, Rodolfo ;
Goswami, Chanchal ;
Safran, Howard ;
dos Santos, Lucas Vieira ;
Aprile, Giuseppe ;
Ferry, David R. ;
Melichar, Bohuslav ;
Tehfe, Mustapha ;
Topuzov, Eldar ;
Zalcberg, John Raymond ;
Chau, Ian ;
Campbell, William ;
Sivanandan, Choondal ;
Pikiel, Joanna ;
Koshiji, Minori ;
Hsu, Yanzhi ;
Liepa, Astra M. ;
Gao, Ling ;
Schwartz, Jonathan D. ;
Tabernero, Josep .
LANCET, 2014, 383 (9911) :31-39
[10]   MBP1: a novel mutant p53-specific protein partner with oncogenic properties [J].
Gallagher, WM ;
Argentini, M ;
Sierra, V ;
Bracco, L ;
Debussche, L ;
Conseiller, E .
ONCOGENE, 1999, 18 (24) :3608-3616